Thierry Léveillard

Dr. Thierry Léveillard

Institut de la Vision: Department of genetics Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012 Paris, France
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TIthe European Alzheimer's Disease Initiative Investigators
the European Alzheimer's Disease Initiative Investigators
JLJean-Charles Lambert
Jean-Charles Lambert
SHSimon Heath
Simon Heath
GEGael Even
Gael Even
DCDominique Campion
Dominique Campion
PAPhilippe Amouyel
Philippe Amouyel

21 December 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LFLars G. Fritsche
Lars G. Fritsche
WIWilmar Igl
Wilmar Igl
JBJessica Cooke Bailey
Jessica Cooke Bailey
FGFelix Grassmann
Felix Grassmann
SSSebanti Sengupta
Sebanti Sengupta
IHIris M. Heid
Iris M. Heid
Iris Heid, Gonçalo Abecasis, Sudha Iyengar and colleagues report the results of a large genome-wide association meta-analysis of macular degeneration based on over 43,000 subjects. They identify 16 new risk loci, including some very rare coding variants. Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 163,714 directly genotyped, mostly rare, protein-altering variants. Analyzing 16,144 patients and 17,832 controls, we identify 52 independently associated common and rare variants (P < 5 × 10−8) distributed across 34 loci. Although wet and dry AMD subtypes exhibit predominantly shared genetics, we identify the first genetic association signal specific to wet AMD, near MMP9 (difference P value = 4.1 × 10−10). Very rare coding variants (frequency <0.1%) in CFH, CFI and TIMP3 suggest causal roles for these genes, as does a splice variant in SLC16A8. Our results support the hypothesis that rare coding variants can pinpoint causal genes within known genetic loci and illustrate that applying the approach systematically to detect new loci requires extremely large sample sizes.

1 May 2015 in Cell
Verified
Journal Article
Closed access
NANajate Aït-Ali
Najate Aït-Ali
RFRam Fridlich
Ram Fridlich
GMGéraldine Millet-Puel
Géraldine Millet-Puel
ECEmmanuelle Clérin
Emmanuelle Clérin
FDFrançois Delalande
François Delalande
Thierry LéveillardThierry Léveillard
Thierry Léveillard

27 June 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
Thierry LéveillardThierry Léveillard
Thierry Léveillard
SMSaddek Mohand-Saïd
Saddek Mohand-Saïd
OLOlivier Lorentz
Olivier Lorentz
DHDavid Hicks
David Hicks
AFAnne-Claire Fintz
Anne-Claire Fintz
JSJosé-Alain Sahel
José-Alain Sahel
Retinitis pigmentosa is an untreatable, inherited retinal disease that leads to blindness. The disease initiates with the loss of night vision due to rod photoreceptor degeneration, followed by irreversible, progressive loss of cone photoreceptor1,2,3. Cone loss is responsible for the main visual handicap, as cones are essential for day and high-acuity vision4. Their loss is indirect, as most genes associated with retinitis pigmentosa are not expressed by these cells. We previously showed that factors secreted from rods are essential for cone viability5,6,7,8. Here we identified one such trophic factor by expression cloning and named it rod-derived cone viability factor (RdCVF). RdCVF is a truncated thioredoxin-like protein specifically expressed by photoreceptors. The identification of this protein offers new treatment possibilities for retinitis pigmentosa.

1 November 2009 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
IAIsabelle Audo
Isabelle Audo
SKSusanne Kohl
Susanne Kohl
BLBart P. Leroy
Bart P. Leroy
FMFrancis L. Munier
Francis L. Munier
Xavier GuillonneauXavier Guillonneau
Xavier Guillonneau
Christina ZeitzChristina Zeitz
Christina Zeitz

21 November 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LBLeah C. Byrne
Leah C. Byrne
DDDeniz Dalkara
Deniz Dalkara
GLGabriel Luna
Gabriel Luna
SFSteven K. Fisher
Steven K. Fisher
ECEmmanuelle Clérin
Emmanuelle Clérin
JFJohn G. Flannery
John G. Flannery
Alternative splicing of nucleoredoxin-like 1 (Nxnl1) results in 2 isoforms of the rod-derived cone viability factor. The truncated form (RdCVF) is a thioredoxin-like protein secreted by rods that promotes cone survival, while the full-length isoform (RdCVFL), which contains a thioredoxin fold, is involved in oxidative signaling and protection against hyperoxia. Here, we evaluated the effects of these different isoforms in 2 murine models of rod-cone dystrophy. We used adeno-associated virus (AAV) to express these isoforms in mice and found that both systemic and intravitreal injection of engineered AAV vectors resulted in RdCVF and RdCVFL expression in the eye. Systemic delivery of AAV92YF vectors in neonates resulted in earlier onset of RdCVF and RdCVFL expression compared with that observed with intraocular injection using the same vectors at P14. We also evaluated the efficacy of intravitreal injection using a recently developed photoreceptor-transducing AAV variant (7m8) at P14. Systemic administration of AAV92YF-RdCVF improved cone function and delayed cone loss, while AAV92YF-RdCVFL increased rhodopsin mRNA and reduced oxidative stress by-products. Intravitreal 7m8-RdCVF slowed the rate of cone cell death and increased the amplitude of the photopic electroretinogram. Together, these results indicate different functions for Nxnl1 isoforms in the retina and suggest that RdCVF gene therapy has potential for treating retinal degenerative disease.